The endothelin system plays a role in the complex pathophysiology of idiopathic dilated cardiomyopathy. We investigated whether genetic polymorphisms of the endothelin system might be associated with dilated cardiomyopathy-related cardiac phenotypes and differences in disease outcome.
Introduction
Idiopathic dilated cardiomyopathy, a heart-muscle disease characterized by biventricular dilatation and impaired myocardial contractility [1] , is a common cause of heart failure and a primary indication for cardiac transplantation [2] . The disease aetiology is multifactorial with a strong genetic component and a familial predisposition is suggested in approximately 25% of dilated cardiomyopathy patients [3] [4] [5] . The endothelin system is involved in the pathophysiology of heart failure since plasma endothelin-1 (ET-1) levels [6, 7] and endothelin-A (ET A ) receptor densities [8, 9] are increased in patients with dilated cardiomyopathy. Apart from endothelial cells [10] , ET-1 is also produced in cardiac myocytes [11] and fibroblasts [12] , exerting its cardiac effects mainly through the ET A receptor [8, 13, 14] . Based on this pathophysiological background we have drawn our hypothesis, that genetic variations in one of the endothelin system components might influence dilated cardiomyopathy-related cardiac phenotypes or the disease course including survival. Recently, several genetic polymorphisms in the genes encoding the endothelin system have been reported [15, 16] and a common genetic polymorphism in the ET A receptor gene has been more frequently found in French patients with dilated cardiomyopathy than in control subjects [17] . The aim of the present study was to investigate whether genetic variations in the genes encoding ET-1, and the receptors ET A and endothelin B (ET B ) might be associated with differences in dilated cardiomyopathy-related cardiac phenotypes and/or clinical outcome in dilated cardiomyopathy patients.
Methods

Study population
One hundred and twenty-five consecutive unrelated patients of a previously well characterized cohort of dilated cardiomyopathy patients were examined by physical examination, 12-lead electrocardiogram (ECG), echocardiography and left heart catheterization including selective coronary angiography [18, 19] . Blood samples were drawn in the Franz-Volhard-Klinik. Informed consent was obtained in accordance with the guidelines of the ethical committee of the Max-Delbrü ck-Center for Molecular Medicine. Echocardiographic evaluation was performed according to the criteria of the American Society of Echocardiography [20, 21] . Angiographic left ventricular ejection fraction was determined by the area-length method [22] . Diagnosis of dilated cardiomyopathy was based on impaired left ventricular function with global hypokinesia and an ejection fraction below the lowest normal ejection fraction for our laboratory (normal ejection fraction >56%) and left ventricular dilatation as a left ventricular end-diastolic diameter above the 95th percentile of a reference range [23] in the absence of any other causes of cardiac dilatation. Because of the high prevalence of coronary artery disease, significant coronary stenosis (>25% luminal reduction) was excluded by selective coronary angiography in each case.
Genotyping of the dilated cardiomyopathy population for ET-1 and the ET A and ET B receptor gene polymorphisms
From the published sequences of the genes encoding ET-1, and the ET A and ET B receptors we used primers as formerly described [15, 16] . Each amplification was performed using 100 ng of DNA in a total volume of 50 l containing 10 mmol . l We genotyped 125 dilated cardiomyopathy patients for the following genetic polymorphisms: ET-1: T1370G, K198N (G/T), +138ex1 ins/del; ET A receptor: H323H (C/T), G+70C; ET B receptor: L277L (G/A). Genotyping was performed using allele-specific oligonucleotides and done as previously described [24] . The oligonucleotide sequences used for polymerase chain reaction and allele-specific oligonucleotides are available at the following web site: http://genecanvas.idf.inserm.fr.
Statistical analysis
Hardy-Weinberg equilibrium was tested by a chi-square test with 1 degree of freedom. Genotype frequencies were compared between the different groups by chisquare-testing. Continuous and categorical variables between groups were compared by t-test and chi-square test. The Mantel-Haenszel weighted odds ratio and the asymptotic 95% confidence interval for common odds ratios were computed for subgroups. Survival curves were estimated by the Kaplan-Meier method. Differences in survival curves were compared using the logrank test, the Breslow test, and the Tarone test. Cox proportional hazards regression was used to analyse the influence of known predictors of prognosis in addition to the gene polymorphisms. Continuous covariates were coded so that the baseline group represented the lowest risk group. Age was entered as the difference in age to the youngest patient, end-diastolic diameter was determined by the difference to the smallest diameter and ejection fraction was entered as the difference from the highest value. Backward, step-wise rejection of variables was employed at the 0·05 significance level. Data were analysed using the SPSS statistical software package release 10.0.
Results
Echocardiographic and angiographic data were available for the entire group of 125 dilated cardiomyopathy patients ( Table 1 ). The mean age of patients was 58 ( 10) years and they were followed-up for a mean period of 40 ( 21) months. One hundred and twenty patients were treated with ACE-inhibitors, 91 received diuretics, 56 patients were treated with digitalis and 40 patients with beta-blockers, 40 patients received nitrates and seven patients amiodarone.
The allelic distributions for all six polymorphisms investigated are reported in Table 2 and for all subsequent analyses carriers of the less frequent alleles were compared with non-carriers.
The clinical characteristics of patients according to the different ET A 323 genotypes are reported in Table 3 . Neither group differed in the severity of heart failure at baseline. However, the ET A receptor gene polymorphism H323H was significantly associated with a shorter cumulative survival (Fig. 1) . The odds ratio for T allele
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carriers to die within 2 years after diagnosis was 5·5 (95% confidence interval, 1·4 to 21·0, P=0·013) compared to non-carriers. Kaplan-Meier analysis revealed a significantly different survival time for T allele carriers as compared to non-carriers as tested by logrank (P=0·0196), Breslow (P=0·0195) and Tarone tests (P=0·020). The influence of the ET A H323H polymorphism on survival remained significant when known predictors of prognosis such as left ventricular ejection fraction, left ventricular end-diastolic diameter, age and New York Heart Association (NYHA) functional classification were entered in a Cox proportional hazards analysis. In this model, end-diastolic diameter showed a trend to influence survival (P=0·07), but the ET A H323H polymorphism (P=0·0029) was a significant independent predictor of survival.
Although ACE inhibitors improve survival in patients with heart failure, we could not evaluate the influence of inhibition of the renin-angiotensin system on prognosis as most of our patients (96%) were already treated with this compound. Only 32% of our patients received beta-blockers at the time of diagnosis because at that time it was not yet proven that beta-blockers improve prognosis. As the MERIT-HF [25] and the CIBIS II [26] studies demonstrated that beta-blockers prolong survival, we included therapy with or without this treatment in the regression model, showing that betablockers had no significant influence on survival. This, however, did not alter the significant influence of the ET A H323H polymorphism on prognosis. Additionally, none of the remaining polymorphisms was significantly related to severity of heart failure or survival in our study. All values are given as means SD.
Discussion
Our main result is that patients carrying the T allele of the ET A receptor gene polymorphism H323H show significantly worse cumulative survival compared to non-carriers. The odds ratio to die within 2 years after diagnosis was 5·5 (95% confidence interval, 1·4-21·0, P=0·013) in T allele carriers compared to non-carriers. Survival was dependent only on the H323H polymorphism and clearly independent of other well established predictors of prognosis such as age, NYHA class, left ventricular ejection fraction, and end-diastolic diameter. To our knowledge, this is the first study to demonstrate a significant relationship between a common genetic polymorphism and survival in patients with dilated cardiomyopathy.
Markers of left ventricular dysfunction are important predictors for survival [2] . To assess their relative influence on survival, we examined, in addition to the ET A H323H polymorphism, the influence of left ventricular end-diastolic diameter, left ventricular ejection fraction, NYHA classification, and age in a multivariate model. End-diastolic diameter showed a trend to influence survival (P=0·07) and all other clinical variables were of no significant influence. Only the ET A H323H variant had an independent significant influence on survival, which clearly suggests an impact of the ET A receptor polymorphism on dilated cardiomyopathy prognosis.
The pathophysiological mechanisms by which this polymorphism might influence survival are not yet elucidated. Possible mechanisms may include an influence of genetic ET A receptor variants on receptor expression 
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and/or function, thereby modulating the influence of ET-1 action on the cardiovascular system. The H323H polymorphism is situated in exon 6 of the ET A receptor gene, encoding the sixth membrane-spanning domain and the third extracellular loop of the protein. The polymorphism substitutes a thymine (T) for a cytosine (C) which does not alter the amino acid sequence of the receptor protein.
Although it is conceivable that this C to T transition might be functional by, for instance, influencing gene transcription or by creating a novel splice site, it appears more likely that this variant might be in linkage disequilibrium with another functional molecular variant which has not yet been identified. The fact that ET A blockade could ameliorate dilated cardiomyopathy disease phenotypes speaks in favour of a gain-of-function mutation with respect to the H323H polymorphism, since T allele carriers experience a worse outcome. This, however, should be evaluated experimentally in appropriate studies. Most interestingly, the ET A receptor has been demonstrated to be upregulated in failing hearts of dilated cardiomyopathy patients [8, 9] . Infusion or short-term oral therapy of an endothelin ET A [27] or mixed ET A /ET B receptor antagonist [28, 29] caused further haemodynamic improvement in patients with heart failure whose reninangiotensin system was already blocked by inhibitors.
Chronic treatment with an ET A receptor antagonist significantly improved survival in rats with chronic heart failure [30] . Furthermore, in cardiomyopathic hamsters and rats with chronic heart failure, chronic treatment with an ET A [31] or the mixed ET A /ET B receptor antagonist bosentan [32, 33] , greatly ameliorated survival and cardiac dysfunction. It is, therefore, conceivable that ET A receptor blockade also improves survival in patients with dilated cardiomyopathy, and that T allele carriers may show greater improvement than noncarriers.
Concerning the vascular system and depending on cardiac disease states, a differential regulation of ET A and ET B receptor expression has also been hypothesized [34, 35] . In that respect, Love and colleagues [36] recently reported that, compared to control subjects, venoconstriction after venous infusion of ET-1 was diminished in patients with chronic heart failure, whereas there was no difference between groups after the infusion of a selective ET B receptor agonist. This led to the suggestion that ET A receptor expression in the venous system might be blunted in patients with chronic heart failure. This might be relevant from a clinical point of view, but should be substantiated by further studies.
In fact, 96% and 32% of our patients received ACE inhibitors and beta-blockers, respectively, so that the activity of the renin-angiotensin system and to a lesser degree the activity of the sympathetic nervous system were reduced. Under these conditions more specific pathophysiological features of the endothelin system might become unmasked and will allow the impact of genetic variants of this system on disease phenotypes to be assessed. Although suggested by two prospective studies [25, 26] , we did not observe any influence of betablocker therapy on survival at the time of diagnosis, possibly due to the later start of beta-blocker therapy in many of our patients. It is well known that ACE inhibitors decrease the progression of heart failure, thereby improving prognosis [37, 38] . Because only 4% of our patients did not receive ACE inhibitors, it was not possible to evaluate the influence of ACE inhibitor therapy on prognosis.
In conclusion, our results strongly suggest a role of a genetic variation in the ET A receptor on survival in dilated cardiomyopathy patients. This might have important consequences for the identification of high-risk individuals and also indicate that ET A antagonists might be beneficial for dilated cardiomyopathy patients. In vitro and additional genetic studies should be performed to assess the potentially functional impact of the ET A H323H polymorphism on receptor expression or structure.
